IP Library Granted Patent US 7,435,804
Granted Patent B2
US 7,435,804 · App. 10/968,757 · Granted Oct 14, 2008

Method for obtaining single chain antibodies to human interferon α2b

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,435,804
App. No.
10/968,757
Granted
Oct 14, 2008
Kind
B2
Abstract

A bacterial high-expression system which is applicable for simultaneous screening of large numbers of recombinant clones from combinatorial antibody libraries is disclosed. The method pertains to screening of single chain antibodies from libraries expressed in the periplasm of E. coli by secretion. By this approach, approximately 10 4 clones can be screened in a single round. After screening, the clones, which express the recombinant antibodies to the desired antigen, can be directly used for production of large quantities of antibodies from microorganism culture. The system is especially attractive for fast screening of antibody libraries from a hybridoma source. A refolding method for the large-scale production of biologically active scFv-6 his proteins from bacterial inclusion bodies is also disclosed.

Claims (20)

1. A method for recovery of a ScFv antibody having the sequence shown in SEQ ID NO:2 or having the sequences shown in SEQ ID NOS: 3 and 4 from E. coli inclusion bodies in biologically active form which comprises:

providing a transformed E. coli cell expressing a nucleic acid sequence encoding the ScFv antibody of SEQ ID NO:2 or SEQ ID NOS: 3 and 4 in the inclusion bodies;

solubilizing the inclusion bodies in a detergent to release the ScFv antibody;

oxidizing the released ScFv antibody to form disulfide bonds;

removing the detergent;

precipitating the oxidized ScFv antibodies;

dissolving the precipitated ScFv antibodies in a denaturing solution;

immobilizing the ScFv antibodies on a solid support;

renaturing ScFv antibodies on the solid support; and

eluting the ScFv antibodies in biologically active form,

wherein the ScFv antibody binds interferon α-2b.

2. The method of claim 1 , wherein the detergent is N-lauroylsarcosine solution.

3. The method of claim 1 , wherein the oxidation takes place in the presence of a Cu 2+ catalyst.

4. The method of claim 1 , wherein the detergent is removed by butanol extraction.

5. The method of claim 1 , wherein the precipitation is by centrifugation.

6. The method of claim 1 , wherein the denaturing solution is a buffered urea solution.

7. The method of claim 1 , wherein the renaturation is performed with a linear phosphate gradient.

8. The method of claim 1 , wherein the solid support is Ni-NTA agarose.

9. An isolated ScFv 17 protein having the sequence shown in SEQ ID NO: 2.

10. An isolated ScFv17 protein having the amino acid sequence shown in SEQ ID NO:3 and the amino acid sequence shown in SEQ ID NO:4.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2010
From: PHAGE BIOTECHNOLOGY CORPORATION
To: NEW TECHNOLOGIES HOLDING PTE. LTD.
Reel/Frame 024351/0625 →
AMENDMENT TO SECURITY AGREEMENT Recorded Aug 25, 2009
From: PHAGE BIOTECHNOLOGY CORPORATION
To: RITTER, RICHARD, COLLATERAL AGENT
Reel/Frame 023134/0152 →
SECURITY AGREEMENT Recorded Nov 24, 2008
From: PHAGE BIOTECHNOLOGY CORPORATION
To: RICHARD RITTER, COLLATERAL AGENT
Reel/Frame 021936/0646 →
TERMINATION OF SECURITY INTEREST Recorded Jan 16, 2007
From: KNOBBE, MARTENS, OLSON & BEAR, LLP
To: PHAGE BIOTECHNOLOGY CORPORATION
Reel/Frame 018767/0483 →
SECURITY INTEREST Recorded Oct 12, 2006
From: PHAGE BIOTECHNOLOGY CORPORATION
To: KNOBBE, MARTENS, OLSON & BEAR, LLP
Reel/Frame 018385/0677 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2004
From: KORDYUM, VITALIY A.; OKUNEV, OLEG; GILCHUK, PAVLO; DERYABINA, OLENA; IRODOV, DMITRO
To: PHAGE BIOTECHNOLOGY CORPORATION
Reel/Frame 015924/0581 →